The first product is expected to be launched shortly, while approvals for the remaining are expected in the next 12-18 months, Caplin Point Laboratories said in a BSE filing.from Moneycontrol Business News https://ift.tt/2AyS598
Tuesday, July 7, 2020
Caplin Point Labs#39; subsidiary inks distribution pact with Xellia Pharmaceuticals for 5 injectables in the US
The first product is expected to be launched shortly, while approvals for the remaining are expected in the next 12-18 months, Caplin Point Laboratories said in a BSE filing.from Moneycontrol Business News https://ift.tt/2AyS598
Subscribe to:
Post Comments (Atom)
-
The value had touched a high of 22% of total market capitalisation of listed firms in June 2009, dropping to a low of 5.1% in September 2020...
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
No comments:
Post a Comment